wherein R_1 is lower alkyl, R_2, R_3, R_4 and R_5 are individually selected from the group consisting of hydrogen, halogen and $-OSO_2R_{10}$, at least one of R_3, R_4 and R_5 being $-OSO_2R_{10}$, R_6 is $-(CH_2)_m-SiR_7R_8R_9$, R_7, R_8 and R_9 are individually lower alkyl, R_{10} is lower alkyl unsubstituted or substituted with at least one halogen or aryl unsubstituted or substituted with at least one lower alkyl, m is an integer from 0 to 6 and its non-toxic, pharmaceutically acceptable salts.

Claim 25 (cancelled)

Claim 26 (currently amended)

A pharmaceutical ~~An antitumoral~~ composition comprising an antitumorally effective amount of a compound of formula (II_A) of claim 24 and an inert carrier.

Claim 27 (currently amended)

A method of treating colon cancer ~~tumors~~ in warm-blooded animals comprising administering to warm-blooded animals in need thereof an ~~antitumorally~~ effective amount of a compound of claim 24 to treat colon cancer.

AMENDMENTS TO THE CLAIMS

Claims 1 to 4 (cancelled)

Claim 5 (currently amended)

A compound of claim 24 which is ~~selected from the group consisting of~~

(5R)-5-ethyl-9,10,difluoro-5-hydroxy-12-(2-trimethylsilylethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino [3',4':6,7]-indoloizino[1,2-b]quinoleine-3,15-dione~~;~~

~~(5R) 5 ethyl 5 hydroxy 12 (2 trimethylsilylethyl) 4,5,13,15 tetrahydro 1H,3H oxepino [3',4':6,7]indolizino[1,2 b]quinoleine 3,15 dione~~.

Claims 6 to 23 (cancelled)

Claim 24 (currently amended)

A compound selected from the group consisting of the formula



(II_A)